Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 17 June 2026Expected publication date: TBC
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 29 June 2026Expected publication date: TBC
Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 29 June 2026Expected publication date: TBC